查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020552

2026-2034年全球活性藥物成分（API）市場規模、佔有率、趨勢和成長分析報告

Global Active Pharmaceutical Ingredients API Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 251 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

活性藥物成分（API）的市場規模預計將從 2025 年的 2,813 億美元成長到 2034 年的 4,801.2 億美元，2026 年至 2034 年的複合年成長率為 6.12%。

全球對藥品和醫療產品的需求不斷成長，正推動全球活性藥物成分（API）市場顯著擴張。 API是藥物中具有生物活性的成分，能夠發揮所需的治療效果。它們是生產多種藥物（包括抗生素、止痛藥和慢性病治療藥物）的必需原料。

原料藥市場的主要驅動力是糖尿病、癌症和心血管疾病等慢性病的盛行率上升。對學名藥需求的成長也促進了全球原料藥產量的擴張。製藥公司正投資先進的生產技術，以提高生產效率並確保高品質的藥物研發。

隨著全球醫療保健需求持續成長，原料藥市場預計將穩定發展。新興市場製藥生產設施的擴張以及研發活動的活性化將支撐市場成長。此外，生物技術和個人化醫療的創新有望為原料藥產業帶來新的機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球活性藥物成分（API）市場：依分子類型分類

  • 市場分析、洞察與預測
  • 乙醯胺酚
  • 萘普生
  • Furosemide
  • 呋喃妥因
  • 磺胺多辛
  • 乙胺嘧啶
  • 阿摩迪亞金
  • 阿扎那韋硫酸鹽
  • 尼姆斯利德
  • Ciprofloxacin
  • 哌拉喹磷酸鹽，索他洛爾
  • 左乙拉西坦
  • 雙氯芬酸鈉
  • 阿奇黴素
  • 其他

第5章 全球活性藥物成分（API）市場：依生產類型分類

  • 市場分析、洞察與預測
  • 內部生產
  • 外包

第6章 全球活性藥物成分（API）市場：依產品類型分類

  • 市場分析、洞察與預測
  • 低活躍度 API
  • 高活動 API

第7章 全球醫藥活性成分（API）市場：依API類型分類

  • 市場分析、洞察與預測
  • 合成
  • 自然的

第8章 全球活性藥物成分（API）市場：依規模分類

  • 市場分析、洞察與預測
  • 飛行員
  • 大規模

第9章 全球活性藥物成分（API）市場：按應用分類

  • 市場分析、洞察與預測
  • 商業的
  • 研究

第10章 全球活性藥物成分（API）市場：按最終用戶分類

  • 市場分析、洞察與預測
  • 製藥公司
  • 生技公司
  • 契約製造公司（CMO）
  • 其他

第11章 全球活性藥物成分（API）市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第12章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第13章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc
    • Mangalam Drugs & Organics Limited
    • Viatris Inc
    • Lonza
    • Piramal Pharma Solutions
    • HISUN USA Inc
    • Ipca Laboratories Ltd
    • AbbVie Inc
    • Alembic Pharmaceuticals Limited
    • Biocon
    • Merck KGaA
    • Boehringer Ingelheim
    • Cambrex Corporation
    • Dr. Reddy's Laboratories Ltd
簡介目錄
Product Code: VMR112116214

The Active Pharmaceutical Ingredients API Market size is expected to reach USD 480.12 Billion in 2034 from USD 281.30 Billion (2025) growing at a CAGR of 6.12% during 2026-2034.

The global active pharmaceutical ingredients (API) market is expanding significantly due to the rising demand for pharmaceutical drugs and medical treatments worldwide. APIs are the biologically active components in medications that produce the desired therapeutic effects. They are essential for the manufacturing of a wide range of pharmaceutical products, including antibiotics, pain relievers, and treatments for chronic diseases.

A key driver of the API market is the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions. The growing demand for generic medicines is also contributing to the expansion of API production globally. Pharmaceutical companies are investing in advanced manufacturing technologies to improve production efficiency and ensure high-quality drug development.

In the future, the API market is expected to grow steadily as global healthcare demand continues to rise. The expansion of pharmaceutical manufacturing facilities in emerging economies and increased research and development activities will support market growth. Additionally, innovations in biotechnology and personalized medicine are expected to create new opportunities in the API industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Molecule Type

  • Acetaminophen
  • Naproxen
  • Furosemide
  • Nitrofurantoin
  • Sulfadoxine
  • Pyrimethamine
  • Amodiaquine
  • Atazanavir Sulfate
  • Nimesulide
  • Ciprofloxacin
  • Piperaquine Phosphate Sotalol
  • Levetiracetam
  • Diclofenac
  • Azithromycin
  • Others

By Production Type

  • Captive/In House
  • Outsourcing

By Product Type

  • Low Potent API
  • High Potent API

By API Type

  • Synthetic
  • Natural

By Scale

  • Pilot
  • Large

By Application

  • Commercial
  • Research

By End User

  • Pharmaceutical Companies
  • Biotechnological Companies
  • Contract Manufacturing Organizations (CMOs)
  • Others

COMPANIES PROFILED

  • Teva Pharmaceutical Industries Ltd, Pfizer Inc, Mangalam Drugs Organics Limited, Viatris Inc, Lonza, Piramal Pharma Solutions, HISUN USA Inc, Ipca Laboratories Ltd, AbbVie Inc, Alembic Pharmaceuticals Limited, Biocon, Merck KGaA, Boehringer Ingelheim, Cambrex Corporation, Dr Reddys Laboratories Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY MOLECULE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Molecule Type
  • 4.2. Acetaminophen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Naproxen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Furosemide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Nitrofurantoin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Sulfadoxine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Pyrimethamine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Amodiaquine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.9. Atazanavir Sulfate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.10. Nimesulide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.11. Ciprofloxacin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.12. Piperaquine Phosphate Sotalol Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.13. Levetiracetam Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.14. Diclofenac Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.15. Azithromycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.16. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY PRODUCTION TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Production Type
  • 5.2. Captive/In House Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Outsourcing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Product Type
  • 6.2. Low Potent API Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. High Potent API Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY API TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Api Type
  • 7.2. Synthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Natural Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY SCALE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Scale
  • 8.2. Pilot Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Large Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Application
  • 9.2. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY END USER 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast End User
  • 10.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Biotechnological Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Contract Manufacturing Organizations (CMOs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY REGION 2022-2034 (USD MN)

  • 11.1. Regional Outlook
  • 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.2.1 By Molecule Type
    • 11.2.2 By Production Type
    • 11.2.3 By Product Type
    • 11.2.4 By Api Type
    • 11.2.5 By Scale
    • 11.2.6 By Application
    • 11.2.7 By End User
    • 11.2.8 United States
    • 11.2.9 Canada
    • 11.2.10 Mexico
  • 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.3.1 By Molecule Type
    • 11.3.2 By Production Type
    • 11.3.3 By Product Type
    • 11.3.4 By Api Type
    • 11.3.5 By Scale
    • 11.3.6 By Application
    • 11.3.7 By End User
    • 11.3.8 United Kingdom
    • 11.3.9 France
    • 11.3.10 Germany
    • 11.3.11 Italy
    • 11.3.12 Russia
    • 11.3.13 Rest Of Europe
  • 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.4.1 By Molecule Type
    • 11.4.2 By Production Type
    • 11.4.3 By Product Type
    • 11.4.4 By Api Type
    • 11.4.5 By Scale
    • 11.4.6 By Application
    • 11.4.7 By End User
    • 11.4.8 India
    • 11.4.9 Japan
    • 11.4.10 South Korea
    • 11.4.11 Australia
    • 11.4.12 South East Asia
    • 11.4.13 Rest Of Asia Pacific
  • 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.5.1 By Molecule Type
    • 11.5.2 By Production Type
    • 11.5.3 By Product Type
    • 11.5.4 By Api Type
    • 11.5.5 By Scale
    • 11.5.6 By Application
    • 11.5.7 By End User
    • 11.5.8 Brazil
    • 11.5.9 Argentina
    • 11.5.10 Peru
    • 11.5.11 Chile
    • 11.5.12 Rest of Latin America
  • 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.6.1 By Molecule Type
    • 11.6.2 By Production Type
    • 11.6.3 By Product Type
    • 11.6.4 By Api Type
    • 11.6.5 By Scale
    • 11.6.6 By Application
    • 11.6.7 By End User
    • 11.6.8 Saudi Arabia
    • 11.6.9 UAE
    • 11.6.10 Israel
    • 11.6.11 South Africa
    • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

  • 12.1. Recent Developments
  • 12.2. Company Categorization
  • 12.3. Supply Chain & Channel Partners (based on availability)
  • 12.4. Market Share & Positioning Analysis (based on availability)
  • 12.5. Vendor Landscape (based on availability)
  • 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Company Profiles
    • 13.2.1 Teva Pharmaceutical Industries Ltd
    • 13.2.2 Pfizer Inc
    • 13.2.3 Mangalam Drugs & Organics Limited
    • 13.2.4 Viatris Inc
    • 13.2.5 Lonza
    • 13.2.6 Piramal Pharma Solutions
    • 13.2.7 HISUN USA Inc
    • 13.2.8 Ipca Laboratories Ltd
    • 13.2.9 AbbVie Inc
    • 13.2.10 Alembic Pharmaceuticals Limited
    • 13.2.11 Biocon
    • 13.2.12 Merck KGaA
    • 13.2.13 Boehringer Ingelheim
    • 13.2.14 Cambrex Corporation
    • 13.2.15 Dr. Reddy's Laboratories Ltd